Swedish Orphan Biovitrum AB


Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.

  • Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
  • We market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies.
  • We have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners. 
  • We manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.